<DOC>
	<DOCNO>NCT01198665</DOCNO>
	<brief_summary>The urgent need new effective therapy T-cell lymphoma patient promise result observe far trial RAD001 ( everolimus , mTOR inhibitor ) strongly warrant investigation RAD001 combine CHOP first-line treatment peripheral T-cell lymphoma patient . Thus , design phase I/II study combination RAD001 CHOP chemotherapy newly diagnose peripheral T-cell lymphoma patient . Phase I 1 . Primary objective : To define maximum tolerable dose 2 . Secondary objective - To evaluate dose-limiting toxicity - To evaluate pharmacokinetics RAD001 - Pharmacogenomic profile Phase II 1 . Primary objective : To evaluate overall response rate 2 . Secondary objective - To estimate time progression - To estimate overall survival - Pharmacogenomic profiling</brief_summary>
	<brief_title>RAD001 Combined With CHOP Newly Diagnosed Peripheral T-cell Lymphomas</brief_title>
	<detailed_description>Phase I Level 1 : RAD001 2.5 mg PO daily D1-14 + CHOP Level 2 : RAD001 5 mg PO daily D1-14 + CHOP Level 3 : RAD001 7.5 mg PO daily D1-14 + CHOP Level 4 : RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 week D1 Cytoxan 750mg/m2 + D5W 100ml MIV 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV 30mins D1 Vincristine 1.4mg/m2 ( max.2mg ) IV push D1-D5 Prednisolone 100mg/d PO ( 40-30-30 ) Phase II Determined dosage RAD001 + CHOP every 3 week Treatment continue plan 6 cycle disease progression</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Histologically proven peripheral Tcell lymphoma , unspecified , ( PTCL ) , ALKnegative anaplastic large cell Tcell lymphoma ( ALCL ) , Angioimmunoblastic T cell lymphoma ( AITL ) , Cutaneous Tcell lymphoma 2 . Adequate organ function define follow criterion : A.Serum aspartate transaminase ( AST ; serum glutamic oxaloacetic transaminase ( SGOT ) ) serum alanine transaminase ( ALT ; serum glutamic pyruvic transaminase ( SGPT ) ) ≤2.5 x local laboratory upper limit normal ( ULN ) , AST ALT less equal 5 x ULN liver function abnormality due underlying malignancy B.Total serum bilirubin ≤1.5 x ULN C.Absolute neutrophil count ( ANC ) ≥1500/µL D.Platelets ≥100,000/µL E.Hemoglobin ≥9.0 g/dL ( may transfuse erythropoietin treat ) F.Serum calcium ≤12.0 mg/dL G.Serum creatinine ≤1.5 x ULN 3 . At least one measurable lesion 4 . ECOG PS 02 5 . Informed consent 6 . Age 20 70 year old 1 . Prior radiation therapy surgery within 4 week prior study entry 2 . History central nervous system ( CNS ) metastases 3 . Ongoing cardiac dysrhythmias NCI CTCAE grade ≥2 . 4 . Pregnancy breastfeed . 5 . Hepatitis B virus surface antigen positive 6 . Extranodal NK/T cell lymphoma 7 . Mycosis fungoides 8 . ALKpositive Anaplastic large cell lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>RAD001</keyword>
	<keyword>chemotherpy</keyword>
	<keyword>T cell lymphoma</keyword>
</DOC>